The association between relative leukocyte telomere length of prostate cancer patients at diagnosis with cancer prognostic parameters
DOI:
https://doi.org/10.52786/isu.a.19Keywords:
Leukocyte telomere length, prostate cancer, castration resistance, metastasis, survivalAbstract
Objectives: In this study, relative leukocyte telomere length (LTL) was investigated as a prognostic marker to evaluate association of LTL at the time of diagnosis and prostate cancer-specific survival, metastasis-free survival, overall survival, with castrate-resistant prostate cancer (CRPC).
Materials and Methods: In this retrospective cohort study, pertinent data from 81 patients were collected. Patients underwent prostate cancer (PCa) treatment procedures determined by staging and current recommendation. Blood samples from suspected PCa patients were obtained before the initiation of diagnosis and treatment. LTL was determined by the quantitative polymerase chain reaction method. Relative LTL was compared to the main clinical outcome measures. Prostate cancer-specific survival, metastasis-free survival, overall survival and CRPC were calculated retrospectively, for a mean follow-up period of 30 months.
Results: This analysis showed relative LTL was not associated with tumor stage, Gleason score, grade group, metabolic disease, or smoking. However, older age was significantly associated with short LTL (p < 0.001). All main outcomes were not associated with LTL. In contrast, a subgroup analysis of patients who underwent primary androgen deprivation therapy (ADT) showed a CRPC association with relatively long LTL (p = 0.039). To our knowledge, these results are novel and give further strength to our hypothesis that relative LTL might be used as a prognostic marker in PCa especially in patients who will receive primary ADT.
Conclusion: Aging was significantly associated with relatively short LTL. There was no significant association between LTL in PCa patients at diagnosis and cancer-specific survival, metastasis-free survival, or overall survival. However, patients who underwent ADT treatment alone showed CRPC associated with relatively long LTL.
References
Gu J. Leukocyte Telomere Length and Cancer risk: A Dynamic Problem. EBio Medicine 2015;2:493-4.
McGrath M, Wong JYY, Michaud D, Hunter DJ, De Vivo I. Telomere length, cigarette smoking, and bladder cancer risk in men and women. Cancer Epidemiol. Biomarkers Prev 2007;16:815-9.
Balasubramanyam M, Adaikalakoteswari A, Monickaraj SF, Mohan V. Telomere shortening & metabolic/vascular diseases. Indian J Med Res 2007;125:441-50.
CE Elks, RA Scott. The Long and Short of Telomere Length and Diabetes, Diabetes 2014;63:65-7.
Zhao J, Zhu Y, Lin J, Matsuguchi T, Blackburn E, Zhang Y, et al. Short leukocyte telomere length predicts risk of diabetes in American Indians: the strong heart family study. Diabetes 2013;63:354-62.
Mahjoub S, Krams M. Comparison of telomerase activity in prostate cancer, prostatic intraepithelial neoplasia and benign prostatic hyperplasia. J Res Med Sci 2006;11:229-33.
Martwachira K, Lojanapiwat B, Kaewtunjai N, Tantiwechapikul W. Investigation into a possible association between telomere length in prostate cancer patients and non-prostate cancer patients. Thai J Urol 2019;40:35-40.
Ma H, Zhou Z, Wei S, Liu Z, Pooley KA, Dunning AM, et al. Shortened telomere length is associated with increased risk of cancer: a meta-analysis. PLoS ONE. 2011;6:e20466.
Chen Y, Qu F, He X, Bao G, Liu X, Wan S, et al. Short leukocyte telomere length predicts poor prognosis and indicates altered immune functions in colorectal cancer patients. Ann Oncol 2014;25:869-76.
Russo A, Modica F, Guarrera S, Fiorito G, Pardini B, Viberti C, et al. Shorter leukocyte telomere length is independently associated with poor survival in patients with bladder cancer. Cancer Epidemiol Biomark Prev 2014;23:2439-46.
Weischer M, Nordestgaard BG, Cawthon RM, Freiberg JJ, Tybjaerg-Hansen A, Bojesen SE. Short telomere length, cancer survival, and cancer risk in 47,102 individuals. J Natl Cancer Inst 2013;105:459-68.
Nan H, Du M, Vivo ID, Manson JE, Liu S, McTiernan A, et al. Shorter telomeres associate with a reduced risk of melanoma development. Cancer Res 2011;71:6758-63.
Xie H, Wu X, Wang S, Chang D, Pollock RE, Lev D, et al. Long telomeres in peripheral blood leukocytes are associated with an increased risk of soft tissue sarcoma. Cancer 2013;119:1885-91.
Sanchez-Espiridion B, Chen M, Chang JY, Lu C, Chang DW, Roth JA, et al. Telomere length in peripheral blood leukocytes and lung cancer risk: a large case-control study in Caucasians. Cancer Res 2014;74:2476-86.
Julin B, Shui I, Heaphy CM, Joshu CE, Meeker AK, Giovannucci E, et al. Circulating leukocyte telomere length and risk of overall and aggressive prostate cancer. Br J Cancer 2015;112:769-76
De Vivo I, Prescott J, Wong JY, Kraft P, Hankinson SE, Hunter D. A prospective study of relative telomere length and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev 2009;18:1152-6.
Weischer M, Nordestgaard BG, Cawthon RM, Freiberg JJ, Tybjaerj-Hansen A, Bojesen SE. Short telomere length, cancer survival, and cancer risk in 47102 individuals. J Natl Cancer Inst 2013;105:459- 68.
Kaszubowska L. Telomere shortening and ageing of the immune system. J Physiol Pharmacol 2008; 59:169-86.
Svenson U, Roos G, Wikström P. Long leukocyte telomere length in prostate cancer patients at diagnosis is associated with poor metastasis-free and cancer-specific survival. Tumour Biol 2017;39:1-7.
Xu J, Chang W, Tsai C, Bau D, Xu Y, Davis JW, et al. Leukocyte telomere length is associated with aggressive prostate cancer in localized prostate cancer patients. EBioMedicine 2020;52:102616.
Cawthon RM. Telomere length measurement by a novel monochrome multiplex quantitative PCR method. Nucleic Acids Res 2009;37:e21.
Shen M, Cawthon R, Rothman N, Weinstein SJ, Virtamo J, Hosgood 3rd HD, et al. A prospective study of telomere length measured by monochrome multiplex quantitative PCR and risk of lung cancer. Lung Cancer 2011;73:133-7.
Merseburger AS, Alcaraz A, von Klot CA. Androgen deprivation therapy as backbone therapy in the management of prostate cancer. Onco Targets Ther 2016;9:7263-74.
Renner W, Krenn-Pilko S, Gruber HJ, Herrmann M, Langsenlehner T. Relative telomere length and prostate cancer mortality. Prostate Cancer Prostatic Dis 2018;21:579-83.
Ji G, Song G, Huang C, He S, Zhou L. Rapidly decreasing level of prostate-specific antigen during initial androgen deprivation therapy is a risk factor for early progression to castration-resistant prostate cancer: a retrospective study. Medicine 2017;96:e7823.
